Last reviewed · How we verify
Bupivacaine, lidocaine, ropivacaine
Bupivacaine, lidocaine, ropivacaine is a Small molecule drug developed by University of California, Los Angeles. It is currently FDA-approved.
Bupivacaine, lidocaine, and ropivacaine are marketed anesthetics developed by the University of California, Los Angeles, with a key composition patent expiring in 2028. The drugs' primary strength lies in their well-established use and safety profile, making them a reliable choice in clinical settings. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Bupivacaine, lidocaine, ropivacaine |
|---|---|
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Comparison of SPSIP Block and SAP Block in Non-Intubated Uniportal VATS. (NA)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Cryo Rib Fracture Study (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Different Peribulbar Blocks With SPI-guided Anaesthesia for VRS (P&MSPIVRS) (NA)
- Comparison Between 2 Techniques for Lumbar-ESPB (NA)
- Peripheral Nerve Blocks vs Selective Spinal Anesthesia in Patients With Femur Fracture (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine, lidocaine, ropivacaine CI brief — competitive landscape report
- Bupivacaine, lidocaine, ropivacaine updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI